Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.

Riboflavin drops are used every 2 minutes for 30+ minutes until the corneal stroma is
saturated with Riboflavin as evidenced by observing Riboflavin in the Anterior chamber. Two
arms in the study, one uses Riboflavin with Epithelium on and the other with Epithelium off.
Once it is observed that the Riboflavin has penetrated the stroma and is seen in the
anterior chamber, the cornea is exposed to Ultraviolet light at an irradiance level of
18mW/cm2 for 5 minutes. A contact lens is applied until the epithelium has fully healed in 3
to 5 days. The study is for 6 months. The corneal curvature as well as the uncorrected and
best corrected vision and corneal thickness are evaluated pre-operatively and at 6 months.
The primary variable that is assessed to determine the efficacy of the drug is the Kmax -
Steep corneal curvature. Secondary effectiveness criteria are uncorrected and best corrected
vision and corneal thickness. adverse events are also monitored.

INCLUSION CRITERIA GENERAL:

1. 12 years of age or older

2. Signed written informed consent

3. Willingness and ability to comply with schedule for follow-up visits

4. Contact lens removal prior to evaluation and treatment

5. Candidates must also have two of the following criteria:

1. Presence of central or inferior steepening on the Pentacam or Orbscan map
consistent with Keratoconus.

2. Axial topography consistent with keratoconus.

3. Steepest keratometry (Kmax) value of 47.00D

INCLUSION CRITERIA FOR ECTASIA:

History of having undergone a keratorefractive procedure and 2 of the following criteria:

1. Steepening by topography, either Pentacam or Orbscan

2. Thinning of cornea

3. Shift in the position of thinnest portion of cornea

4. Change in refraction with increasing myopia

5. Development of myopic astigmatism

6. Development of irregular astigmatism

7. Loss of BSCVA

EXCLUSION CRITERIA:

I. Eyes classified as either normal or atypical normal 2. Corneal pachymetry 350
microns at the thinnest point measured by Pentacam in the eye to be treated 3. A
history of chemical injury or delayed epithelial healing in the eye to be treated.

4. Pregnancy (including plan to become pregnant) or lactation during the course of
the study 5. A known sensitivity to study medications 6. Patients with nystagmus or
any other condition that would prevent a steady gaze during the treatment 7.
Inability to cooperate with diagnostic tests. 8. Patients with a concomitant
condition that, in the investigator's opinion, would interfere with or prolong
epithelial healing.

9. Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking
treatment.

10. Patients who are unable to remain supine and tolerate a lid speculum for an
extended period of time.